Poster Awards: SOHO 2023
Hematology/oncology specialists gathered from around the world at the global annual meeting of the Society of Hematologic Oncology. More than 600 attendees submitted an abstract for poster presentation, oral presentation and/or publication during the event.
Eight awards were presented for best posters:
FIRST PLACE ⭐
Loretta J. Nastoupil, MD | MD Anderson Cancer Center, Houston, TX, USA | IBCL-098: TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)
SECOND PLACE ⭐
Natalie Callander, MD | University of Wisconsin Carbone Cancer Ctr, Madison, WI, USA | CT-356: Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)
THIRD PLACE ⭐
Elias Jabbour, MD | MD Anderson Cancer Center, Houston, TX, USA | ALL-300: First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
HONORABLE DISTINCTION
Faye Feller, MD | Geron Corporation, Parsippany, NJ, USA | MDS-572: Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III
HONORABLE DISTINCTION
Harry Erba, MD, PhD | Duke Cancer Institute, Durham, CA, USA | AML-475: Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML
HONORABLE DISTINCTION
Yasmin Karimi, MD | University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA | ABCL-500: Longer follow-up reaffirms subcutaneous epcoritamab induces deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: updated results from the pivotal EPCORE NHL-1 trial
HONORABLE DISTINCTION
Naveen Pemmaraju, MD | MD Anderson Cancer Center, Houston, TX, USA | MPN-498: Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion
HONORABLE DISTINCTION
Richard F. Schlenk, MD | Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany | CT-186: Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
Oral Abstracts: SOHO 2023
SOHO 2023 General Sessions included a number of oral abstract presentations during the annual meeting. Abstracts considered for oral presentation were drawn from a select group of outstanding submissions. The following oral abstracts were presented during the meeting:
- ALL-300: First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
- ALL-363: Comparison of Treatment Outcomes in Adolescents and Young Adults (AYA) With Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Treated With HyperCVAD and Pediatric-Inspired Protocols (PIPs)
Omar Shahin MBChB
King Hussein Cancer Center, Amman, Jordan
- MDS-044: Cancer Disparities in Survival of Patients With Hematologic Malignancies in the Context of Social Determinants of Health: A Systematic Review
Marisol Miranda-Galvis, PhD
Georgia Cancer Center, Augusta, Georgia, USA
- MDS-157: Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX, USA
- AML-112: Impact of Consolidation Chemotherapy Intensity Before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia
Yosr Hicheri, MD
Institut Paoli Clamettes, Marseille, France
- CML-310: Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX, USA
- MPN-470: Examining Racial Disparities in Primary Myelofibrosis Incidence and Survival Rates: A SEER Database Analysis from 2000‒2019
M Bakri Hammami, MD
Albert Einstein College of Medicine, New York, New York, USA
- MM-304: Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Yi Lin, MD, PhD
Mayo Clinic Rochester, Rochester, Minnesota, USA
- CLL-094: Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study
Tanya Siddiqi MD
City of Hope Cancer Center, Duarte, California, USA
- IBCL-098: TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)
Loretta J. Nastoupil, MD
MD Anderson Cancer Center, Houston, Texas, USA
- ABCL-500: Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial
Yasmin Karimi, MD
University of Michigan, Ann Arbor, Michigan, USA
- HL-642: Does Interim PET Assessment After Two Cycles of Treatment With Brentuximab Vedotin Still Have a Predictive Value in Hodgkin Lymphoma?
Ravand Samaeekia, MD, MS
Loma Linda University Cancer Center, Loma Linda, California, USA
- CT-186: Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
Alexander Perl, MD, MS
University of Pennsylvania, Philadelphia, Pennsylvania, USA
SOHO 2023 Abstract Proceedings